SD Biotech Summit -Animal Health Panel

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Vaccines and Related Biological Products
Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.
Reorganization of APHIS Veterinary Services U.S. Department of Agriculture Animal and Plant Health Inspection Service Veterinary Services November 2013.
1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.
Public and Private Interests in Animal Research LAT Chapter 1.
Preventive Herd Health and Vaccination Cow/Calf Production Unit.
John Naim, PhD Director Clinical Trials Research Unit
Telemedicine Credentialing and Privileging October 16, 2014.
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Veterinary education in Europe Pierre Lekeux University of Liege, Belgium Foz de Iguazu, December 2013.
1 The FDA and Animal Drug Compounding Neal Bataller, DVM FDA/Center for Veterinary Medicine AAVPT 14 th Biennial Symposium, May 16-17, 2005, Rockville,
MICHIGAN DEPARTMENT OF AGRICULTURE A NIMAL INDUSTRY DIVISION JOAN M. ARNOLDI, D.V.M., M.S. State Veterinarian and Division Director NANCY A. FRANK, D.V.M.,
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
Towards a global plan to fight against bioterrorism in synergy with Russian Federation Novosibirsk
Regulatory Overview.
Biotechnology Careers Objective Primary Careers Areas of concentration Areas of concentration Horticulture – growing fruits, veggies, and ornamental.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
ISCB-SC - Saraswathi.S Saraswathi S PhD Student Iowa State University Ames, Iowa, USA Chairperson: ISCB-SC-RSG.
RAISING THE BAR Meeting CSA Guidelines And Preparing for Health Canada
Developing responsible and ethical laboratory animal care and use programs which benefit the well being of animals while mutually working together with.
Global Recognition of the Indian Biotech Sector - The Road Ahead Sept 26,2003 Hyderabad.
Case Study SummaryChallenges Boston Scientific needed medical translation in different areas in the medical field, including technical, legal and corporate.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
The Biotech Industry and Careers Why choose a career in Biotechnology? Because you can help save lives, cure diseases, help feed the hungry, help create.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
R EGULATORY A GENCIES What are regulatory issues? Types of agencies How they affect you Top 10 regulatory issues.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
Health Canada’s Approach to Low Risk Veterinary Health Products: Interim Notification Pilot Program Veterinary Drugs Directorate-Health Canada Presented.
Regulatory Perspective on Trends in Veterinary Biologics Byron Rippke, DVM Nancy Clough, DVM, PhD Director, Center for Veterinary Biologics U.S. Department.
1 VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER 2015, TOKYO VICH AND VETERINARY MEDICINES AVAILABILITY VICH5 CONFERENCE, OCTOBER.
Fostering Antimicrobial Stewardship in Animals: Overview of FDA Activities William Flynn, DVM, MS Deputy Director for Science Policy Center for Veterinary.
Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.
The Regulation on Cell Therapy Products in Japan
Regulatory Agencies What are regulatory issues? Types of agencies How they affect you Top 10 regulatory issues.
Registration requirements for vaccines -Strategies to implement VICH GLs- Takashi KOZASA, DVM National Veterinary Assay Laboratory, Ministry of Agriculture,
NASC Audit Program & State Registrations. NASC Audit Program & State Registrations.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
FDA's Two New Draft Guidance on Software and Device
Track 11 Symposium 27 June :30 – 3:00 PM
נמטוציטים משושנת ים Eli. S Lec. No.2.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Veterinary Pharmacovigilance Discussion
Clinical Engineering Lecture (3).
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Renewal Animal Training
The Lifecycle of Pharmaceutical products
Veterinary Technician or Assistant
Waiving Target Animal Batch Safety Testing for vaccines
Program Overview for Oklahoma
MONOJO Biotech Services Centre.
US REGULATORY UPDATE: IMPACT OF FSMA & VFD ON THE AQUACULTURE INDUSTRY
MONOJO Biotech Services Centre.
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Biological Products Industry Alliance Symposium
GL50(R)- HARMONISATION OF CRITERIA TO WAIVE TARGET ANIMAL BATCH SAFETY TESTING FOR INACTIVATED VACCINES FOR VETERINARY USE ( May 2017) GL55- HARMONISATION.
ADVAC ALUMNI MEETING DURING SAGE
Computer System Validation
OSU Controlled Substances Training Module for Researchers
Biocom CRO Presents: Concept to Commercial: A Clinical and Regulatory Outlook October 11, 2017.
GC University Lahore Quality Enhancement Cell
Use an Appropriate Veterinarian/Client/Patient Relationship (VCPR) as the Basis for Medication Decision-Making Good Production Practice #1 Assuring Quality.
Presentation transcript:

SD Biotech Summit -Animal Health Panel PENNY Carpenter Sattgast 04October2018

Agenda 1 2 3 4 5 Animal Health Biologics Experience Education and Career History 2 Animal Health Biologics Experience 3 PCS Biotech Services Overview 4 Examples of PCS Biotech Projects 5 Alternative Animal Health Vaccines

Education: Master of Science: Biology Microbiology and Infectious Disease Emphasis South Dakota State University, Brookings, SD Bachelor of Science: Biology for Information Systems Dakota State University, Madison, SD

-PCS Biotech Services, LLC -Novartis Animal Health Career History Corporate Biotech Sales Business Owner -PCS Biotech Services, LLC President & Founder -StarMark Cabinetry Designer Sales Sales skills Construction Knowledge Cabinetry Product Knowledge Design Skills Autocad Drafting Skills Accounting Skills -Grand Laboratories Scientist -Novartis Animal Health Senior Scientist & Project Manger -Elanco Animal Health Senior Scientist & Clinical Trial Study Director Government: Former President of the Harrisburg, SD School Board

Disease Model Experience Swine Challenge Model Bovine Challenge Model BRSV BVD Rotavirus Coronavirus K99 M. Bovis H.Somnus IBR PI3 M Haemolytica Influenza K88 987P F41 K99 Erysipelas H.Parasuis P.Multocida Actinobacillus 1,5, 7

Laboratory and Clinical Experience Clinical (Large and Small Animal) Virology Bacteriology Serology Cell Culture Assay Development Vaccine Formulation Upstream Bioreactors (Suspension Cell & Microcarriers) Animal Handling Vaccination Bleeding Challenge Administration Clinical Observation Scoring

Regulatory Experience USDA Path to Licensure for Biologics Outline of Production Manufacturing Reference Qualification Animal Welfare (IACUC) Regulatory for Global Marketing Studies GCP and GLP Project Management State Vet approvals, 103.3’s USDA-CVB Electronic Data Submissions Pharmacovigilance (Adverse Events) FDA-CVM CFIA

Quality and Project Management Experience Study Monitoring Laboratory and Clinical Process SOPs Data Management and Quality Control Clinical Study execution for internal and 3rd Party Protocol/Study Design Development Statisticians Data analysis and management Technical Report Writing

-Project scopes of all sizes are welcome. Penny (Carpenter) Sattgast, MS Penny founded PCS Biotech Services, LLC in March of 2017. Prior to that, Penny worked for Elanco Animal Health and served as a Clinical Trial Study Director and Scientist. While working full time for Novartis Animal Health, Penny attended South Dakota State University in Brookings, SD where she earned a Master’s degree in Microbiology in 2013. Penny brings 14 years of diverse clinical management and laboratory experience in the biologics industry to her business. -Formed LLC in March 2017 -Based in Pierre, SD -Bring 15 years of diverse clinical study management, disease model, and regulatory/compliance experience to PCS Biotech -Quality focus and on-time delivery of projects are the cornerstones of PCS Biotech Services. -Project scopes of all sizes are welcome.

Pierre, South Dakota

PCS Biotech Professional Services Clinical Trial Management (Non-GxP and GCP, and GLP) Protocol Writing Final Study Report Writing Project Management Study Design Regulatory Support Data Management Data summary & QC Case Report Form Design IACUC Support Study Monitoring Laboratory Support General Consulting GLP consulting Clinical Field Support Quality Control Pharmacovigilance Support Advocacy Lobbying Marketing Teaching Public Speaking

Large Animal Health Companies Small Start-Up Animal Health Companies Mid-Size Animal Health Companies Contract Research Organizations Small Human Health Companies Always looking to add to the list! Clients -South Dakota -Minnesota -Iowa -Nebraska -Florida -Missouri -Idaho

PCS Biotech Projects: Project Management for Clinical Efficacy Trials 1 All-inclusive 2 Smaller Scope

PCS Biotech Projects: Regulatory Guidance on Licensure Pathway Plant based, orally delivered product (feed additive Classification to determine if the product is under FDA or USDA jurisdiction Outline the process and studies for approval of an animal health biologic product through USDA guidelines under 9 CFR Outcome: From a Biologics perspective, it is not as important on HOW the product is made for classification, (i.e.; generated from animals or other methods), but more importantly on WHAT THE CLAIM IS that it protects against.

More PCS Biotech Regulatory Projects -Project Vetting for startup company: Veterinary diagnostic kit Expansion of product License to Canada -FDA Import Permit regulations and Processes for India manufactured IVP to be conducted in the united States

PCS Biotech “On-Site” CRO Projects -Clinical Field support -Challenge and Necropsy Day -Clinical Study Master File Audits -Laboratory support -Study monitoring

PCS Biotech Quality-Based Projects: Quality Systems Implementation Gap analysis between sites and/or functions Quality Project Management for (21CFR) GLP Clinical Study Preparedness

 Bringing Alternative Vaccines to Market: Production and Prescription Platform Product Biologics The USDA-Center for Veterinary Biologics (CVB) allows biologics manufacturers to use advanced technologies to license products -Manufactured with a standardized production platform (PP). CVB recognizes the need and desire to get new or updated products to the market faster Source: Program 2: Panel Discussion-The Regulatory View from USDA - Diagnostics, Guidance on Platforms and Prescriptions, and Bringing Alternative Vaccines to Market-Senior Staff Veterinarian USDA APHIS VS STAS Dr. Amy Gill Presentation from “Animal Health in the Heartland” Symposium, July 2018-Platform and Prescription Platform Biologics

 Production Platform Product Biologics Veterinary Services Memorandum 800.213 & 800.214 utilizes a single “backbone” vector or expression system (VES) Has a standard process for inserting a gene(s) of interest (GOI) into the backbone Generates different recombinant Seeds or Sequences(constructs). -Used to produce product following a standardized method for manufacture. -The final product is non- replicating and nonviable. Source: USDA Veterinary Services Memorandum NO. 800.213 & 800.214

Production Platform Product Biologics Continued In general, a Platform is defined by: Initial Product Vector or Expression System (VES) Gene (antigen) of Interest (GOI) Manufacturing Process Efficacy/Safety After initial product, reduced minimum requirements to license subsequent GOI variants Source: Program 2: Panel Discussion-The Regulatory View from USDA - Diagnostics, Guidance on Platforms and Prescriptions, and Bringing Alternative Vaccines to Market-Senior Staff Veterinarian USDA APHIS VS STAS Dr. Amy Gill Presentation from “Animal Health in the Heartland” Symposium, July 2018-Platform and Prescription Platform Biologics

 Prescription Platform Product Biologics Veterinary Services Memorandum 800.214 Custom veterinary biological product prepared for an individual animal or animals under a prescription written by a licensed veterinarian. Tested for safety and purity, but no efficacy claims Based on initial product fully licensed as described for a Platform Product Source: Program 2: Panel Discussion-The Regulatory View from USDA - Diagnostics, Guidance on Platforms and Prescriptions, and Bringing Alternative Vaccines to Market-Senior Staff Veterinarian USDA APHIS VS STAS Dr. Amy Gill Presentation from “Animal Health in the Heartland” Symposium, July 2018-Platform and Prescription Platform Biologics

Prescription Platform Product Biologics Continued The platform is considered “established” No changes can occur except the inserted GOI, but not limited to just GOI variants… Different GOI can be swapped for the original GOI Limited to species, age, dose, route and maximum antigenic content established in licensed initial product Source: Program 2: Panel Discussion-The Regulatory View from USDA - Diagnostics, Guidance on Platforms and Prescriptions, and Bringing Alternative Vaccines to Market-Senior Staff Veterinarian USDA APHIS VS STAS Dr. Amy Gill Presentation from “Animal Health in the Heartland” Symposium, July 2018-Platform and Prescription Platform Biologics

Thank You! https://pcsbiotechservices.com/